Despite decades of research, mesenchymal stem/stromal cell (MSC) therapy development has fallen short of expectations. Although regulatory convention prioritizes viability-centric metrics as proxies for potency, emerging evidence indicates that, in specific in... ...

请注册登录后继续浏览